WIKIMEDIA COMMONS, TIBOR KADEK
Some biochemical companies are selling an erroneous isomer of the Src kinase inhibitor bosutinib to researchers studying the compound for its potential as a chemotherapeutic agent. Originally developed at Wyeth (now Pfizer), bosutinib is currently available from a variety of unlicensed vendors, but they aren’t all selling the same product, according to a recent study that identified a mismarketed isomer that differed from bosutinib in its structure and binding affinity.
“In 32 years [in the biochemical industry], I’ve only seen one other example like this,” said Paul D. Driedger, president of PKC Pharma, a small molecules biotech near Boston, Massachusetts that owns LC Laboratories, one of the vendors that has been selling the incorrect bosutinib. His company began investigating the problem last year when a ...
